CN102286003B - Manufacture method of ceftazidime compound - Google Patents
Manufacture method of ceftazidime compound Download PDFInfo
- Publication number
- CN102286003B CN102286003B CN 201110223500 CN201110223500A CN102286003B CN 102286003 B CN102286003 B CN 102286003B CN 201110223500 CN201110223500 CN 201110223500 CN 201110223500 A CN201110223500 A CN 201110223500A CN 102286003 B CN102286003 B CN 102286003B
- Authority
- CN
- China
- Prior art keywords
- ceftazime
- apca
- reaction
- described step
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Cephalosporin Compounds (AREA)
Abstract
The invention relates to a method for preparing ceftazidime. The synthesis method comprises the following steps: by taking 7-aminocephalosporanic acid (7-ACA) as a starting raw material, introducing a pyridine ion to 3-position methylene of 7-ACA so as to obtain 7-amino-3-(1-picolyl)-cephem acid (7-APCA) hydrochloride; then introducing a side chain with a thiazole ring on 7-position amino of the 7-APCA hydrochloride through acylation reaction; and carrying out hydrolyzing reaction, refining reaction and the like so as to obtain ceftazidime. The synthesis method for preparing the ceftazidime inthe invention is simple to operate and high in yield, and is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of synthetic method of cynnematin, be specifically related to a kind of method for preparing the ceftazime compound, belong to technical field of medicine synthesis.
Ceftazime is the strongest microbiotic of anti Bacillus pyocyaneu Flugge effect in the third generation cephalosporin of GlaxoSmithKline PLC company initiative, is used for septicemia, lower respiratory infection, abdominal cavity and biliary tract infection, complicacy urinary tract infections and serious skin soft-tissue infection etc. due to the responsive gram negative bacilli.Particularly applicable for central nervous system infection due to the immune deficiency person's infection, nosocomial infection and the gram negative bacilli that are caused by the several drug resistance gram negative bacilli or the Pseudomonas aeruginosa.The production technique of commonly using is to introduce first pyridine to 7-ACA C-3 position, and then (WO:85 04659,1985-10-24.) for this condenses and ceftazime 7 β position side chain active thioesters reaction generation ceftazimes.
Ceftazime; chemical name is (6R; 7R)-7-[[(2-amino-4-thiazolyl)-1-[(1-carboxyl-1-methyl ethoxy) imino-] ethanoyl] amino]-2-carboxyl-8-oxo-5-thia-1-azabicyclo [4,2,0] oct-2-ene-3-picoline inner salt.Structural formula is:
At present, bibliographical information prepares ceftazime 3 kinds of diverse ways: first method is as initial parent nucleus take 7-amino-cephalosporanic acid (7-ACA), under the effect of Iodotrimethylsilane (TMS I), react with pyridine, obtain 7-A PCA dihydrochloride, this disalt and BPTA reaction, obtain the ceftazime tert-butyl ester, this tert-butyl ester obtains ceftazidime pentahydrate through steps such as hydrolysis again, pentahydrate and yellow soda ash are mixed and made into injection bulk drug (Jiang Fengyang, the progress [J] that ceftazime is synthetic. Shenyang chemical industry, 1996 (3): 22-25.).Second method is as initial parent nucleus take 7-phenylacetamide-3-chloromethyl cephalosporin alkyl acid p-methoxybenzyl ester (GCL E), react with potassiumiodide, obtain ceftazime intermediate 7-phenylacetylamino-3-iodomethyl-3-cephalosporin-4-carboxyl acid to methoxybenzyl ester, this intermediate and pyridine carry out the series reaction such as nucleophilic substitution obtain target product (Liu Yuting. third generation cephalosporin-ceftazime synthesising process research [D]. Shenyang: Shenyang Pharmaceutical University, 2007.).The third method is that the intermediate 7-ACA that popularizes take domestic contrast is as starting raw material; with hexamethyldisilazane as silylation reagent; adopt rare gas element ammonia excretion and new impurity removing technology; make ceftazidime pentahydrate through 3 substitution reactions, 7 acylation reactions; finally obtain the target compound ceftazime (Zheng Yulin. the improvement in synthesis of ceftazime [J]. Chinese pharmaceutical chemistry magazine, 2010 (3): 198-200.).
Because aforesaid method exists reactions steps long, productive rate is lower, the ceftazime crystal mass is unstable, the shortcomings such as the rear by-product contamination of reaction is larger, the present invention proposes a kind of preparation method of ceftazime of suitable suitability for industrialized production newly, simple to operate, yield is high, gained ceftazime crystalline product quality is good.This operational path is simple to operate, with low cost, compares total recovery with existing technique and greatly improves.
Summary of the invention
For the problems referred to above, the object of the present invention is to provide that a kind of to overcome the prior art reactions steps long, productive rate is lower, and the ceftazime crystal mass is unstable, the preparation method of the ceftazime of the larger shortcoming of by-product contamination after the reaction.
The present invention for achieving the above object, the technical scheme of taking is, a kind of preparation method of ceftazime, the method comprises:
Take 7-amino-cephemcarboxylic acid (7-ACA) as starting raw material; introduce pyridinium ion at the 3-position of 7-ACA methylene radical and obtain 7-amino-3-(1-picolyl) cephemcarboxylic acid (7-APCA) hydrochloride; then on the 7-of 7-APCA hydrochloride bit amino, introduce side chain with thiazole ring by acylation reaction, obtain ceftazime through hydrolysis, refining reaction etc. again.
Detailed Description Of The Invention
The present invention relates to a kind of preparation method of ceftazime, it comprises following four steps:
Take 7-amino-cephemcarboxylic acid (7-ACA) as starting raw material; introduce pyridinium ion at the 3-position of 7-ACA methylene radical and obtain 7-amino-3-(1-picolyl) cephemcarboxylic acid (7-APCA) hydrochloride; then on the 7-of 7-APCA hydrochloride bit amino, introduce side chain with thiazole ring by acylation reaction, obtain ceftazime through hydrolysis, refining reaction etc. again.
Specifically reactions steps is following describes in detail:
Step (1): 7-ACA 50g is joined in the 188ml organic solvent I, then adds the 68ml hexamethyldisilazane, reflux 35～45 ℃ of lower stirring heating; Add trimethylchlorosilane, 35ml Iodotrimethylsilane under xylidene(s) catalysis, continue reaction 5 hours, detect 7-ACA by high performance liquid phase residual, 7-ACA≤0.5% reaction finishes.Add the 30ml pyridine; After finishing, reaction in 2～3 hours adds successively methyl alcohol, dilute hydrochloric acid, layering, and water added activated carbon decolorizing 20 minutes, filtered; Add C-I alcohol in the filtrate and do dispersion agent, transfer PH to 1.0～1.5 with triethylamine, stir a large amount of crystallizations, continuing to drop to pH value is 2.5～3.5.Suction filtration, after washed with isopropyl alcohol, vacuum-drying obtains the crystal of hydrochloride 62.2g of required product 7-APCA; Mass yield 124.4%, purity 99.2%;
Step (2): 50g 7-APCA and 70 g α-(thiazolamine-4-yl)-α-[(spy-butoxy carbonyl) isopropyl oxygen imino] acetic acid sulfydryl benzene isothiazole ester are joined in the solvent of 188ml methylene dichloride and 32ml methyl alcohol, then add the 32ml triethylamine.10～15 ℃ of reactions 10～12 hours detect 7-APCA residual, and when 7-APCA≤0.5%, reaction finishes, and is cooled to 0～5 ℃, growing the grain.Filter, use the washed with dichloromethane filter cake, being filtered dry after the final vacuum drying must ceftazime tert-butyl ester 74.6g, mass yield 149.2%, purity 98.9%;
Step (3): ceftazime tertiary butyl ester 50 g are dissolved in dilute hydrochloric acid: the weight ratio of formic acid is in the mixing solutions of 2:1～3:2, room temperature reaction.Slowly add acetone in the filtrate, carry out crystallization, after the filtering and washing, wet product vacuum-drying obtains ceftazime dihydrochloride 45.5g, mass yield 91%, purity 99.2%;
Step (4): ceftazime dihydrochloride 50 g are dissolved in the frozen water, and decolouring is filtered, filtrate is in the time of 0～5 ℃, with NaOH, yellow soda ash weight ratio be the mixing solutions of 2:1 to regulate pH value be 4.0～4.2, growing the grain is to separating out in a large number, with sour 5 times repeatedly adjust pH be 4.0～4.2, then adjust pH to 3.6～3.8, growing the grain, suction filtration is used respectively cold water, washing with acetone filter cake and dry, obtain white ceftazime crystal 4 7.3g, mass yield 94.6%.
Organic solvent I is selected from methylene dichloride, chloroform, ethyl acetate or tetracol phenixin in the above-mentioned steps (1), preferably from methylene dichloride.
C-I alcohol is selected from methyl alcohol, ethanol, propyl alcohol, Virahol, butanols and isopropylcarbinol in the above-mentioned steps (1), preferably from Virahol.
In the above-mentioned steps (1) trimethylchlorosilane, Iodotrimethylsilane are mixed as silylating reagent.
Above-mentioned steps does not need to pass into nitrogen protection in (1).
Above-mentioned steps does not need to add catalyzer in (2).
Above-mentioned steps (4) is that to regulate the pH value be 4.0～4.2 for the mixing solutions of 2:1 with NaOH, yellow soda ash weight ratio.
Above-mentioned steps (4) is that to regulate the pH value be 4.0 for the mixing solutions of 2:1 with NaOH, yellow soda ash weight ratio.
Compared with prior art, the claimed technical scheme of the present invention has following advantage:
(1), prior art adopts and to prepare first the 7-APCA(7-amino-3-propenylcephalosporaacid acid) iodate, then prepare the 7-APCA hydrochloride, need the reaction of two steps.And the present invention adopts a step to prepare the 7-APCA hydrochloride, and the process time is short, and yield is high; In the selection of dispersion agent, the C-I alcohols of adding selects Virahol to do dispersion agent, and alcoholic solvent toxicity is low, easily recycling, and the environmental protection that more becomes is beneficial to the protection of healthy and environment;
(2), do not need to pass into nitrogen protection, but be beneficial to the discharge of ammonia by the optimization of equipment, not only saved but also environmental protection and safety;
(3), trimethylchlorosilane, Iodotrimethylsilane are mixed as silylating reagent, the hydrochloride cost of product 7-APCA is low, and quality is good, is beneficial to the production control of the ceftazime tert-butyl ester;
(4), under xylidene(s) protection, the consumption of Iodotrimethylsilane is few;
(5), in the preparation process of 7-APCA hydrochloride, regulate pH value with triethylamine, slowly transfer, the control speed of separating out, crystallization is slow, purity is high, intermediates purity (HPLC method) reaches 99%.In addition, by product is siloxanes or organoalkoxysilane, is easy to separate recycling, and " three wastes " are easy to process;
(6), prior art adopts catalyzer in step 2, the present invention does not adopt catalyzer.Because the purity of the hydrochloride of 7-APCA is high, utilizes faster stirring velocity, by adjusting the consumption of methylene dichloride, methyl alcohol, triethylamine, improve temperature of reaction, fast reaction speed obtains purity high equally, the ceftazime tert-butyl ester of Functionality, quality and appealing design.Adopt the method for " cooking all things in one pot " and do not need the crystallization of ethyl acetate, not only reduce the solvent kind, shorten the process time, and be beneficial to large production control and environment protection;
(7), in the preparation process of ceftazime dihydrochloride, adjust concentration and the proportioning of formic acid, hydrochloric acid, utilize the acetone crystallization, both improved the purity of intermediate, improved again the yield of product.
The present invention relates to a kind of preparation method of ceftazime, it comprises following four steps, further comprises:
Step (1): the preparation method of 7-APCA hydrochloride, it may further comprise the steps:
(1) 1 part of 7-ACA (7-amino-cephalosporanic acid) is joined in 5 parts the organic solvent I, adds 1 part of hexamethyldisilazane again, refluxed about 5 hours 40～45 ℃ of lower stirring heating;
(2) under the xylidene(s) protection, add 0.05 part of trimethylchlorosilane, 1 part of Iodotrimethylsilane, continue reaction 5 hours, add 0.6 part of pyridine, by high performance liquid phase detection reaction process;
(3) (7-ACA residual≤0.5%) reaction finishes, and adds methyl alcohol, dilute hydrochloric acid, and layering, water added activated carbon decolorizing 20 minutes, filtered;
(4) add 0.5～2 part of C-I alcohols in the filtrate and do dispersion agent, transfer PH to 1.0～1.5 with triethylamine, be stirred to crystallization and separate out in a large number, continue to drop to the terminal point pH value and reach 2.8～3.0.Suction filtration, after 0.5 part of C-I alcohols washing, wet product vacuum-drying obtains the crystal of hydrochloride of required product 7-APCA, mass yield 〉=124%, purity 〉=99%.
Step (2): the preparation of the ceftazime tert-butyl ester, it may further comprise the steps:
(1) 1 part of 7-APCA and 1.2～1.8 parts of α-(thiazolamine-4-yl)-α-[(spy-butoxy carbonyl) isopropyl oxygen imino] acetic acid sulfydryl benzene isothiazole esters (TAEM) are joined in the solvent of 5 parts of methylene dichloride and 0.5～0.8 part of methyl alcohol, stir and be cooled to 4 ℃;
(2) keep temperature to add 0.5～0.8 part of triethylamine after 5 minutes, temperature is controlled at 10～15 ℃;
After (3) 10 hours, detect 7-APCA residual, by high performance liquid phase monitoring 7-APCA residual≤can be considered reaction during 2mg/ml finishes;
(4) be cooled to 0～3 ℃, growing the grain 3 hours.Filter, with about 1 part of washed with dichloromethane filter cake, being filtered dry must the ceftazime tert-butyl ester behind the dry 4h of final vacuum.Mass yield 〉=148%, purity 〉=98%.
Step (3): the preparation method of ceftazime dihydrochloride, it may further comprise the steps:
(1) 1 part of ceftazime tertiary butyl ester is dissolved in 2 parts concentrated hydrochloric acid, formic acid and water (in the mixing solutions of concentrated hydrochloric acid: formic acid: the weight ratio 2:1:1 of water～3:2:2), room temperature reaction, until the ceftazime tert-butyl ester is residual≤0.5% visual response finishes;
(2) added activated carbon decolorizing 20 minutes, filter, with a small amount of purified water washing charcoal cake;
(3) slowly add acetone in the filtrate, carry out solvent crystal, when crystal solution occurs little when muddy, stop adding solvent, stirred slowly growing the grain 0.5 hour, after continuing to add remaining solvent, restir growing the grain 1 hour, after the filtering and washing, wet product vacuum-drying obtains the ceftazime dihydrochloride.Mass yield 〉=90%, product purity (HPLC method 〉=98%).
Step (4): the preparation method of ceftazime, it may further comprise the steps:
(1) 1 part of ceftazime dihydrochloride is dissolved in 2～4 parts the frozen water, to this solution filter;
(2) filtrate is in the time of 0～5 ℃, pH transferred in 4.0,2 hours in 2 hours with the mixing solutions (the weight ratio 2:1 of NaOH and yellow soda ash) of NaOH, yellow soda ash and at the uniform velocity transfers pH to 3.6 with 3M HCl, growing the grain 3 hours;
(3) suction filtration with cold water, washing with acetone filter cake and dry, gets the white crystal product, mass yield 〉=93%, content 〉=98%.
Employing the inventive method prepares the ceftazime tert-butyl ester, the ceftazime dihydrochloride is simple to operate, yield is high, is fit to suitability for industrialized production.
Embodiment
Following examples only are used for further specifying the present invention, but do not limit the present invention.
[embodiment 1] 7-APCA's is synthetic
To join 1.0 gram 7-ACA (7-amino-cephalosporanic acid) in 5.0 methylene dichloride that restrain, add again 1.0 gram hexamethyldisilazanes, reflux about 5 hours 35～45 ℃ of lower stirring heating.Under xylidene(s) catalysis, add 0.05 gram trimethylchlorosilane, 1.0 gram Iodotrimethylsilanes, continue reaction 5 hours, add 1 gram pyridine, by high performance liquid phase detection reaction process.When record 7-ACA residual≤0.5% the time, reaction finishes, and adds methyl alcohol, dilute hydrochloric acid, layering, water added activated carbon decolorizing 20 minutes, filtered.Then in filtrate, add 0.5～2.0 gram Virahol and do dispersion agent, transfer PH to 1.0～1.2 with triethylamine, be stirred to crystallization and separate out in a large number, continue to drop to the terminal point pH value and reach 2.8～3.0.Suction filtration, after 0.5 gram washed with isopropyl alcohol, wet product vacuum-drying obtains crystal of hydrochloride 1.246 grams of required product 7-APCA, mass yield 124.6%, purity 99.12%.
Synthesizing of [embodiment 2] ceftazime tert-butyl ester
1.0 gram 7-APCA and 1.8 gram α-(thiazolamine-4-yl)-α-[(spy-butoxy carbonyl) isopropyl oxygen imino] acetic acid sulfydryl benzene isothiazole esters (TAEM) are joined in the solvent of 5 gram methylene dichloride and 0.7 gram methyl alcohol, stir and be cooled to 4 ℃.Keep temperature to add 0.7 gram triethylamine after 5 minutes, temperature is controlled at 0～10 ℃.After 10 hours, detect 7-APCA residual, by high performance liquid phase monitoring 7-APCA residual≤can be considered reaction during 2mg/ml finishes.Be cooled to 0～3 ℃, growing the grain 3 hours.Filter, use the washed with dichloromethane filter cake, be filtered dry behind the dry 4h of final vacuum to such an extent that the ceftazime tert-butyl ester 1.482 restrains.Mass yield 148.2%.Ceftazime tert-butyl ester purity 98.1% in the product after testing.
Synthesizing of [embodiment 3] ceftazime dihydrochloride
1.0 gram ceftazime tertiary butyl ester are dissolved in the hydrochloric acid, formic acid of 2 grams, and (in the mixing solutions of hydrochloric acid: the weight ratio 2:1 of formic acid～3:2), room temperature reaction is until the ceftazime tert-butyl ester residual≤0.5% visual response finishes.Slowly add acetone in the filtrate, carry out solvent crystal, when crystal solution occurs little when muddy, stop adding solvent, stirred slowly growing the grain 0.5 hour, after continuing to add remaining solvent, restir growing the grain 1 hour, after the filtering and washing, wet product vacuum-drying obtains ceftazime dihydrochloride 0.91 gram.Mass yield 91%, after testing ceftazime dihydrochloride product purity 98.3% in the product.
Synthesizing of [embodiment 4] ceftazime
1.0 gram ceftazime dihydrochlorides are dissolved in the frozen water of 4 grams, to this solution filter; Filtrate transfers to pH in 4.0,2 hours in 2 hours with the mixing solutions (the weight ratio 2:1 of NaOH and yellow soda ash) of NaOH, yellow soda ash and at the uniform velocity to transfer pH to 3.6 with 3M HCl, growing the grain 3 hours in the time of 0～5 ℃; Suction filtration with cold water, washing with acetone filter cake and dry, gets white crystal product 0.937 gram, mass yield 93.7%, content 98.2%.
Claims (4)
1. the synthetic method of the ceftazime compound shown in the formula (I),
It is characterized in that, comprise following four synthesis steps:
Step (1): 7-ACA is joined in the organic solvent I, then adds hexamethyldisilazane, reflux 35～45 ℃ of lower stirring heating; Under xylidene(s) catalysis, add trimethylchlorosilane, Iodotrimethylsilane, continue reaction 5 hours, add pyridine; Reaction adds methyl alcohol, dilute hydrochloric acid after finishing successively, layering, and aqueous phase adds the C-I alcohols and does dispersion agent, transfers PH to 1.0～1.5 with triethylamine, stirs a large amount of crystallizations, growing the grain 30 minutes, continuing to drop to pH value is 3.0～3.5; Suction filtration, after the washing of C-I alcohol, vacuum-drying obtains the crystal of hydrochloride of required product 7-APCA;
Step (2): 7-APCA and α-(thiazolamine-4-yl)-α-[(spy-butoxy carbonyl) isopropyl oxygen imino] acetic acid sulfydryl benzene isothiazole ester are joined in the solvent of methylene dichloride and methyl alcohol, then add triethylamine, 10～15 ℃ were reacted 10～12 hours, detect 7-APCA residual, when 7-APCA≤0.5%, reaction finishes; Be cooled to 0～5 ℃, growing the grain; Filter, use the washed with dichloromethane filter cake, being filtered dry after the final vacuum drying must the ceftazime tert-butyl ester;
Step (3): the ceftazime tertiary butyl ester is dissolved in concentrated hydrochloric acid: the formic acid weight ratio is in the mixing solutions of 2:1～3:2, room temperature reaction; Slowly add acetone in the filtrate, carry out crystallization, after the filtering and washing, wet product vacuum-drying obtains the ceftazime dihydrochloride;
Step (4): the ceftazime dihydrochloride is dissolved in the frozen water, filters, filtrate is in the time of 0～5 ℃, be that the mixing solutions of 2:1 is regulated pH value, growing the grain, suction filtration with NaOH, yellow soda ash weight ratio, with cold water, washing with acetone filter cake and dry, obtain white ceftazime crystal;
Organic solvent I is selected from one or both mixture of methylene dichloride, chloroform, ethyl acetate and tetracol phenixin in the described step (1);
C-I alcohol is selected from methyl alcohol, ethanol, propyl alcohol, Virahol, butanols or isopropylcarbinol in the described step (1);
Described step does not need to pass into nitrogen protection in (1);
Described step does not need to add catalyzer in (2).
2. the synthetic method of ceftazime compound according to claim 1 is characterized in that, in the described step (1) trimethylchlorosilane, Iodotrimethylsilane is mixed as silylating reagent.
3. the synthetic method of ceftazime compound according to claim 1 is characterized in that, it is 4.0～4.2 that described step (4) is regulated initial pH value.
4. the synthetic method of ceftazime compound according to claim 1 is characterized in that, it is 3.6～3.8 that described step (4) is regulated endpoint pH.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110223500 CN102286003B (en) | 2011-08-05 | 2011-08-05 | Manufacture method of ceftazidime compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110223500 CN102286003B (en) | 2011-08-05 | 2011-08-05 | Manufacture method of ceftazidime compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102286003A CN102286003A (en) | 2011-12-21 |
| CN102286003B true CN102286003B (en) | 2013-03-06 |
Family
ID=45332779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110223500 Active CN102286003B (en) | 2011-08-05 | 2011-08-05 | Manufacture method of ceftazidime compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102286003B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103044457B (en) * | 2012-10-22 | 2014-07-02 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
| CN102875576A (en) * | 2012-10-31 | 2013-01-16 | 苏州致君万庆药业有限公司 | Synthesis of antibiotic ceftazidime, ceftazidime for injection and preparation method of ceftazidime |
| CN102964359A (en) * | 2012-11-23 | 2013-03-13 | 苏州中联化学制药有限公司 | Method for preparing ceftazidime dihydrochloride |
| CN103030651B (en) * | 2012-12-25 | 2014-03-12 | 深圳华润九新药业有限公司 | Method for preparing ceftazidime hydrochloride |
| CN104860964A (en) * | 2015-04-27 | 2015-08-26 | 四川制药制剂有限公司 | Product zero load avoiding injection ceftazidime preparation method |
| CN104761570A (en) * | 2015-04-27 | 2015-07-08 | 四川制药制剂有限公司 | Preparation technology for ceftazidime for injection |
| CN104892638B (en) * | 2015-05-28 | 2017-08-01 | 齐鲁安替制药有限公司 | The method that one kettle way prepares cefotaxime |
| CN105646541B (en) * | 2015-12-30 | 2018-01-30 | 广东金城金素制药有限公司 | A kind of former development quality cefotaxime and its pharmaceutical preparation |
| CN109111467A (en) * | 2017-06-22 | 2019-01-01 | 宁应 | One kind 51/4His acridine compound of head spore and its drug combination preparation |
| CN110396104B (en) * | 2018-07-26 | 2020-10-27 | 赛法洛抗生素有限公司 | New indication of Taistin ceftazidime medicinal preparation for treating gynecological infection |
| CN109912625B (en) * | 2019-03-04 | 2021-01-12 | 辽宁美亚制药有限公司 | Process method for reducing ceftazidime impurity H |
| CN113583023A (en) * | 2021-06-24 | 2021-11-02 | 山东睿智医药科技有限公司 | Process method for preventing ceftazidime tert-butyl ester from generating ceftazidime H impurities |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182383A (en) * | 1986-09-10 | 1993-01-26 | Biochemie Gesellschaft M.B.H. | Stable, crystalline form of a cephalosporin intermediate product |
-
2011
- 2011-08-05 CN CN 201110223500 patent/CN102286003B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182383A (en) * | 1986-09-10 | 1993-01-26 | Biochemie Gesellschaft M.B.H. | Stable, crystalline form of a cephalosporin intermediate product |
Non-Patent Citations (5)
| Title |
|---|
| 刘煜婷.第三代头孢菌素——头孢他啶合成工艺研究.《中国优秀博硕士学位论文全文数据库(硕士)工程科技Ⅰ辑（月刊）》.2007,第2007卷(第01期),第B016-169页. * |
| 头孢他啶合成的研究进展;姜凤阳;《沈阳化工》;19960930(第3期);第3期 * |
| 头孢他啶的合成工艺改进;郑玉林;《中国药物化学杂志》;20100630;第20卷(第3期);第198-200页 * |
| 姜凤阳.头孢他啶合成的研究进展.《沈阳化工》.1996,(第3期),第3期. |
| 郑玉林.头孢他啶的合成工艺改进.《中国药物化学杂志》.2010,第20卷(第3期),第198-200页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102286003A (en) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102286003B (en) | Manufacture method of ceftazidime compound | |
| CN102391289B (en) | Synthetic methods of ceftazidime intermediate and ceftazidime | |
| CN102268019B (en) | Cefadroxil compound and preparation method thereof | |
| CN101613361A (en) | Preparing cefoxitin sodium | |
| JP2013518829A (en) | Synthesis method of dasatinib and its intermediate | |
| CN102002060B (en) | Preparation method of cefozopran hydrochloride | |
| CN103467495A (en) | Method for preparing cefixime compound | |
| CN101696214B (en) | Cefminox sodium compound of new route | |
| CN102167705B (en) | Preparation method of cefmenoxime hydrochloride | |
| CN103030651B (en) | Method for preparing ceftazidime hydrochloride | |
| CN102180892B (en) | Novel method for purifying cefmetazole sodium | |
| CN102816172A (en) | Preparation process of cefamandole nafate | |
| CN103571907A (en) | Separation and purification method for cefaclor by enzymatic synthesis | |
| CN104193765A (en) | Method for synthesizing cefixime | |
| CN104447800A (en) | Synthesis technology of cefoxitin acid | |
| CN103467496A (en) | Preparing method of 7-((thiazolyl hydroxyl imino group) acetamido)-3-methyl cephalosporanic acid and another purpose | |
| CN101786963B (en) | Synthesis method of Azasetron intermediate | |
| CN104277053A (en) | High purity cefodizime and preparation method for intermediate cefodizime acid | |
| CN110407857B (en) | Preparation process of cefathiamidine | |
| CN102040616A (en) | Preparation method of cefozopran hydrochloride | |
| CN102617506B (en) | Preparation method of cefdinir and its intermediate | |
| CN102898441A (en) | Method for synthesizing cefotiam | |
| CN101735239B (en) | Preparation method of anhydrous olanzapine crystal form II | |
| CN103833772B (en) | A kind of synthetic method of cephalosporin | |
| CN101486720B (en) | Method for synthesizing cefodizime sodium compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221021 Address after: No. 68, Limin West 4th Street, Limin Development Zone, Harbin, Heilongjiang 150500 Patentee after: HARBIN PHARMACEUTICAL GROUP HOLDING Co.,Ltd. Patentee after: MEDSHINE DISCOVERY Inc. Address before: No.109 Xuefu Road, Nangang District, Harbin, Heilongjiang 150046, No.1 Junmin Street, Xiangfang District Patentee before: MEDSHINE DISCOVERY Inc. |
|
| TR01 | Transfer of patent right |